Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Conditions: Primary Mediastinal Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Etoposide Phosphate; Drug: Prednisolone; Drug: Rituximab; Drug: Vincristine Sulfate; Drug: Filgrastim; Drug: Pegfilgrastim; Drug: Nivolumab 40 mg in 4 ml Injection Sponsors: National Research Center for Hematology, Russia Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials